Table 2.
Crude incidence rates (IR), crude hazard ratios (cHR) and adjusted hazard ratios (aHR) with 95% confidence intervals (CI) for the effect of initiating HAART (I) compared to deferring HAART (D) at baseline on time to first AIDS event or death and death alone stratified by CD4 count.
| AIDS or Death | Death | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CD4 cells/µL |
PY FUu | IR/1000 PY* | IR/1000 PY* | ||||||||
| Eventsu | D | I | cHR (95%CI) | aHR (95%CI) | Eventsu | D | I | cHR (95%CI) | aHR (95%CI) | ||
| 0–49 (Nu =183) | 664 | 102 | 193.3 | 55.0 | 0.30 (0.19, 0.48) | 0.32 (0.17, 0.59) | 44 | 88.8 | 21.2 | 0.23 (0.12, 0.46) | 0.37 (0.14, 0.95) |
| 50–199 (Nu =1,521) | 6934 | 353 | 56.6 | 22.0 | 0.36 (0.28, 0.47) | 0.48 (0.31, 0.74) | 144 | 27.8 | 9.7 | 0.34 (0.24, 0.50) | 0.55 (0.28, 1.07) |
| 200–349 (Nu =4,459) | 22106 | 732 | 29.4 | 18.7 | 0.62 (0.51, 0.75) | 0.59 (0.43, 0.81) | 261 | 14.1 | 8.9 | 0.64 (0.50, 0.83) | 0.71 (0.44, 1.15) |
| 350–499 (Nu =5,527) | 29653 | 815 | 20.8 | 17.2 | 0.82 (0.66, 1.03) | 0.75 (0.49, 1.14) | 277 | 9.1 | 7.5 | 0.81 (0.57, 1.14) | 0.51 (0.33, 0.80) |
| 500–799 (Nu =5,162) | 28631 | 696 | 18.5 | 14.9 | 0.79 (0.59, 1.05) | 1.10 (0.67, 1.79) | 237 | 8.5 | 6.8 | 0.78 (0.51, 1.20) | 1.02 (0.49, 2.12) |
Nu=unique individuals within the CD4 stratum; PY FUu=unique person-years of follow-up within the CD4 stratum. Eventsu=unique events within the CD4 stratum. aHR adjusted via weighting for injection drug use, HIV test interval <30 days (indicator of seroconversion illness), female sex, time since seroconversion, age, calendar year, HCV co-infection, HBV co-infection, CD4 cell count, days between last CD4 count and start of follow-up, CD4 nadir, number of prior CD4 measures, most recent viral load (log10), days between last viral load and start of follow-up, peak viral load (log10), and number of prior viral load measures. Reference group for all estimates is comprised of subcohort observations during which HAART was not initiated during the index month.